SUPN logo

Supernus Pharmaceuticals, Inc. (SUPN) Cash From Financing

Annual CFF:

$12.19M+$410.07M(+103.06%)
December 31, 2024

Summary

  • As of today, SUPN annual cash from financing is $12.19 million, with the most recent change of +$410.07 million (+103.06%) on December 31, 2024.
  • During the last 3 years, SUPN annual cash from financing has risen by +$142.61 million (+109.35%).
  • SUPN annual cash from financing is now -96.76% below its all-time high of $376.44 million, reached on December 31, 2018.

Performance

SUPN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSUPNcash flow metrics

Quarterly CFF:

$935.00K+$22.33M(+104.37%)
June 30, 2025

Summary

  • As of today, SUPN quarterly cash from financing is $935.00 thousand, with the most recent change of +$22.33 million (+104.37%) on June 30, 2025.
  • Over the past year, SUPN quarterly cash from financing has dropped by -$723.00 thousand (-43.61%).
  • SUPN quarterly cash from financing is now -99.75% below its all-time high of $367.71 million, reached on March 31, 2018.

Performance

SUPN Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSUPNcash flow metrics

TTM CFF:

-$11.50M-$723.00K(-6.71%)
June 30, 2025

Summary

  • As of today, SUPN TTM cash from financing is -$11.50 million, with the most recent change of -$723.00 thousand (-6.71%) on June 30, 2025.
  • Over the past year, SUPN TTM cash from financing has dropped by -$15.59 million (-381.15%).
  • SUPN TTM cash from financing is now -103.04% below its all-time high of $377.88 million, reached on June 30, 2018.

Performance

SUPN TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSUPNcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

SUPN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+103.1%-43.6%-381.1%
3Y3 Years+109.3%-58.9%+92.6%
5Y5 Years+210.4%-34.9%-756.0%

SUPN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+103.1%-98.8%+100.2%-112.5%+97.6%
5Y5-Yearat high+103.1%-98.8%+100.2%-112.5%+97.6%
All-TimeAll-Time-96.8%+103.1%-99.8%+100.2%-103.0%+97.6%

SUPN Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
$935.00K(+104.4%)
-$11.50M(-6.7%)
Mar 2025
-
-$21.40M(-463.3%)
-$10.78M(-188.4%)
Dec 2024
$12.19M(+103.1%)
$5.89M(+91.5%)
$12.19M(+64.9%)
Sep 2024
-
$3.08M(+85.5%)
$7.39M(+80.8%)
Jun 2024
-
$1.66M(+5.6%)
$4.09M(+100.9%)
Mar 2024
-
$1.57M(+43.8%)
-$476.48M(-19.8%)
Dec 2023
-$397.88M(-3697.7%)
$1.09M(+574.8%)
-$397.88M(-0.4%)
Sep 2023
-
-$230.00K(+100.0%)
-$396.14M(-1.7%)
Jun 2023
-
-$478.92M(-697.3%)
-$389.46M(-524.6%)
Mar 2023
-
$80.17M(+2734.0%)
$91.73M(+975.5%)
Dec 2022
-$10.48M(+92.0%)
$2.83M(-56.2%)
-$10.48M(+93.0%)
Sep 2022
-
$6.46M(+184.0%)
-$150.05M(+3.3%)
Jun 2022
-
$2.27M(+110.3%)
-$155.18M(-0.3%)
Mar 2022
-
-$22.03M(+83.9%)
-$154.70M(-18.6%)
Dec 2021
-$130.42M(-3764.5%)
-$136.74M(>-9900.0%)
-$130.42M(-1489.1%)
Sep 2021
-
$1.32M(-51.8%)
$9.39M(+32.5%)
Jun 2021
-
$2.75M(+22.3%)
$7.09M(+22.7%)
Mar 2021
-
$2.25M(-26.8%)
$5.77M(+62.2%)
Dec 2020
$3.56M(-9.4%)
$3.07M(+413.5%)
$3.56M(+103.0%)
Sep 2020
-
-$979.00K(-168.1%)
$1.75M(-41.1%)
Jun 2020
-
$1.44M(+4390.6%)
$2.97M(-6.4%)
Mar 2020
-
$32.00K(-97.5%)
$3.18M(-19.1%)
Dec 2019
$3.93M(-99.0%)
$1.26M(+421.9%)
$3.93M(+0.3%)
Sep 2019
-
$242.00K(-85.2%)
$3.92M(-13.0%)
Jun 2019
-
$1.64M(+109.5%)
$4.50M(-52.7%)
Mar 2019
-
$783.00K(-37.4%)
$9.51M(-97.5%)
Dec 2018
$376.44M(+6526.3%)
$1.25M(+51.1%)
$376.44M(+0.0%)
Sep 2018
-
$828.00K(-87.5%)
$376.36M(-0.4%)
Jun 2018
-
$6.65M(-98.2%)
$377.88M(+1.4%)
Mar 2018
-
$367.71M(>+9900.0%)
$372.79M(+6462.0%)
Dec 2017
$5.68M
$1.17M(-50.1%)
$5.68M(+7.0%)
DateAnnualQuarterlyTTM
Sep 2017
-
$2.35M(+50.4%)
$5.31M(+64.8%)
Jun 2017
-
$1.56M(+158.3%)
$3.22M(+27.2%)
Mar 2017
-
$604.00K(-24.2%)
$2.53M(+23.4%)
Dec 2016
$2.05M(+9.9%)
$797.00K(+206.5%)
$2.05M(-0.1%)
Sep 2016
-
$260.00K(-70.1%)
$2.06M(+10.9%)
Jun 2016
-
$871.00K(+602.4%)
$1.85M(+0.5%)
Mar 2016
-
$124.00K(-84.5%)
$1.84M(-1.2%)
Dec 2015
$1.87M(-93.9%)
$800.00K(+1279.3%)
$1.87M(+36.0%)
Sep 2015
-
$58.00K(-93.3%)
$1.37M(+3.3%)
Jun 2015
-
$862.00K(+486.4%)
$1.33M(+86.7%)
Mar 2015
-
$147.00K(-52.0%)
$712.00K(+24.9%)
Dec 2014
$30.57M(-51.3%)
$306.00K(+2085.7%)
$570.00K(+147.9%)
Sep 2014
-
$14.00K(-94.3%)
-$1.19M(+2.6%)
Jun 2014
-
$245.00K(+4800.0%)
-$1.22M(-101.9%)
Mar 2014
-
$5000.00(+100.3%)
$63.77M(+1.6%)
Dec 2013
$62.74M(-28.6%)
-$1.45M(-7977.8%)
$62.74M(-41.1%)
Sep 2013
-
-$18.00K(-100.0%)
$106.57M(+2.1%)
Jun 2013
-
$65.23M(+6489.0%)
$104.36M(+18.7%)
Mar 2013
-
-$1.02M(-102.4%)
$87.95M(+0.0%)
Dec 2012
$87.92M(+224.6%)
$42.38M(+2004.5%)
$87.92M(+45.5%)
Sep 2012
-
-$2.23M(-104.6%)
$60.43M(-1.5%)
Jun 2012
-
$48.82M(+4718.9%)
$61.34M(+356.9%)
Mar 2012
-
-$1.06M(-107.1%)
$13.43M(-50.4%)
Dec 2011
$27.09M(+2969.4%)
$14.89M(+1230.4%)
$27.09M(+122.0%)
Sep 2011
-
-$1.32M(-244.4%)
$12.20M(-9.7%)
Jun 2011
-
$912.00K(-92.8%)
$13.52M(+7.2%)
Mar 2011
-
$12.61M
$12.61M
Dec 2010
-$944.00K(-122.1%)
-
-
Dec 2009
$4.28M(-93.4%)
-
-
Dec 2008
$64.46M(>+9900.0%)
-
-
Dec 2007
$5000.00
-
-

FAQ

  • What is Supernus Pharmaceuticals, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Supernus Pharmaceuticals, Inc.?
  • What is Supernus Pharmaceuticals, Inc. annual cash from financing year-on-year change?
  • What is Supernus Pharmaceuticals, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Supernus Pharmaceuticals, Inc.?
  • What is Supernus Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
  • What is Supernus Pharmaceuticals, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Supernus Pharmaceuticals, Inc.?
  • What is Supernus Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

What is Supernus Pharmaceuticals, Inc. annual cash from financing?

The current annual cash from financing of SUPN is $12.19M

What is the all-time high annual cash from financing for Supernus Pharmaceuticals, Inc.?

Supernus Pharmaceuticals, Inc. all-time high annual cash from financing is $376.44M

What is Supernus Pharmaceuticals, Inc. annual cash from financing year-on-year change?

Over the past year, SUPN annual cash from financing has changed by +$410.07M (+103.06%)

What is Supernus Pharmaceuticals, Inc. quarterly cash from financing?

The current quarterly cash from financing of SUPN is $935.00K

What is the all-time high quarterly cash from financing for Supernus Pharmaceuticals, Inc.?

Supernus Pharmaceuticals, Inc. all-time high quarterly cash from financing is $367.71M

What is Supernus Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?

Over the past year, SUPN quarterly cash from financing has changed by -$723.00K (-43.61%)

What is Supernus Pharmaceuticals, Inc. TTM cash from financing?

The current TTM cash from financing of SUPN is -$11.50M

What is the all-time high TTM cash from financing for Supernus Pharmaceuticals, Inc.?

Supernus Pharmaceuticals, Inc. all-time high TTM cash from financing is $377.88M

What is Supernus Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

Over the past year, SUPN TTM cash from financing has changed by -$15.59M (-381.15%)
On this page